ClinicalTrials.gg
CompletedNCT01380730LAPLACEUpdated Nov 15, 2022Results posted

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

A Phase 2 interventional study of Evolocumab and Placebo to Evolocumab in Hyperlipidemia, sponsored by Amgen. Completed at 100 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-15.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
631
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.

Enrollment
4th of 21
631 · median 307
Started
2011
with 2 others
Phase 2
3 of 21
none open now
Registered
4th of 21
by date
Lead sponsor
16 of 21
Amgen

Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 4th largest by enrollment, is one of 3 that started in 2011, is one of 3 in phase 2, and was the 4th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing evolocumab in Hyperlipidemias as a file.
02

Study summary

To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab (AMG 145) administered every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on percent change from baseline in LDL-C when used in addition to a statin in adults with hypercholesterolemia.

03

Conditions studied

  • Hyperlipidemia

Keywords

  • Hypercholesterolemia
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 to ≤ 80 years of age
  • On an approved statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks
  • Fasting LDL-C ≥ 85 mg/dL
  • Fasting triglycerides ≤ 400 mg/dL

Exclusion criteria

Exclusion Criteria:

  • Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization
  • Type 1 diabetes; newly diagnosed or poorly controlled type 2 diabetes (Glycosyated () > 8.5%)
  • Uncontrolled hypertension
  • (NYHA) III or IV heart failure, or known \< 30%
  • Uncontrolled cardiac arrhythmia
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
631 participants (actual)

Study arms

  • Placebo comparator
    Placebo Q2W

    Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.

    Other: Placebo to Evolocumab

  • Placebo comparator
    Placebo Q4W

    Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.

    Other: Placebo to Evolocumab

  • Experimental
    Evolocumab 70 mg Q2W

    Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 105 mg Q2W

    Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 140 mg Q2W

    Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 280 mg Q4W

    Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 350 mg Q4W

    Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 420 mg Q4W

    Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection

    Also known as: AMG 145, Repatha

  • OtherPlacebo to Evolocumab

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

    LDL-C was measured using ultracentrifugation.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in LDL-C at Week 12

    LDL-C was measured using ultracentrifugation.

    Time frame: Baseline and Week 12

  2. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12

    Time frame: Baseline and Week 12

  3. Percent Change From Baseline in Apolipoprotein B at Week 12

    Time frame: Baseline and Week 12

  4. Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12

    Time frame: Baseline and Week 12

  5. Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12

    Time frame: Baseline and Week 12

07

Results

Posted Oct 1, 2015

Participant flow

This study enrolled adults aged 18 - 80 years who were on a statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks, and fasting low-density lipoprotein cholesterol (LDL-C) ≥ 85 mg/dL. The first patient enrolled on 18 July 2011 and the last patient enrolled on 22 December 2011.

Participant flow — Overall Study
MilestonePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Started7879797978797980
Received treatment7877797978797980
Completed7879797977797980
Not completed00001000
Withdrew: Death00001000

Outcome measures

PrimaryPercent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

LDL-C was measured using ultracentrifugation.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
percent changePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 122.76 ± 2.39-0.98 ± 2.51-39.06 ± 2.39-57.48 ± 2.39-63.34 ± 2.40-42.82 ± 2.52-50.98 ± 2.51-51.31 ± 2.53
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -66.10 · 95% CI -71.48 to -60.72Placebo is the reference
  • Placebo Q2W vs Evolocumab 105 mg Q2W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -60.24 · 95% CI -65.61 to -54.88Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -41.82 · 95% CI -47.18 to -36.45Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -50.33 · 95% CI -56.04 to -44.62Placebo is the reference
  • Placebo Q4W vs Evolocumab 350 mg Q4W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -50.00 · 95% CI -55.69 to -44.31Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -41.84 · 95% CI -47.55 to -36.13Placebo is the reference
SecondaryChange From Baseline in LDL-C at Week 12

LDL-C was measured using ultracentrifugation.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at Week 12
mg/dLPlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Change From Baseline in LDL-C at Week 12-0.2 ± 3.4-3.2 ± 3.3-50.9 ± 3.4-77.6 ± 3.5-79.5 ± 3.4-53.7 ± 3.3-64.3 ± 3.3-64.3 ± 3.3
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -79.2 · 95% CI -87.0 to -71.5Placebo is the reference
  • Placebo Q2W vs Evolocumab 105 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -77.4 · 95% CI -85.2 to -69.6Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -50.7 · 95% CI -58.5 to -43.0Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -61.1 · 95% CI -68.6 to -53.7Placebo is the reference
  • Placebo Q4W vs Evolocumab 350 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -61.1 · 95% CI -68.5 to -53.7Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -50.6 · 95% CI -58.0 to -43.1Placebo is the reference
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
percent changePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 122.21 ± 2.20-1.26 ± 2.26-36.23 ± 2.20-53.21 ± 2.20-59.19 ± 2.21-39.05 ± 2.27-47.05 ± 2.26-48.83 ± 2.27
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -61.40 · 95% CI -66.37 to -56.43Placebo is the reference
  • Placebo Q2W vs Evolocumab 105 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -55.42 · 95% CI -60.37 to -50.47Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -38.44 · 95% CI -43.39 to -33.48Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -47.58 · 95% CI -52.72 to -42.44Placebo is the reference
  • Placebo Q4W vs Evolocumab 350 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -45.80 · 95% CI -50.92 to -40.67Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -37.79 · 95% CI -42.94 to -32.65Placebo is the reference
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at Week 12
percent changePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline in Apolipoprotein B at Week 125.86 ± 2.153.22 ± 2.25-28.88 ± 2.15-44.29 ± 2.14-50.59 ± 2.15-31.16 ± 2.26-37.55 ± 2.26-38.81 ± 2.27
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -56.45 · 95% CI -61.28 to -51.61Placebo is the reference
  • Placebo Q2W vs Evolocumab 105 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -50.15 · 95% CI -54.97 to -45.33Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -34.74 · 95% CI -39.56 to -29.92Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -42.03 · 95% CI -47.16 to -36.90Placebo is the reference
  • Placebo Q4W vs Evolocumab 350 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -40.77 · 95% CI -45.88 to -35.66Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -34.38 · 95% CI -39.51 to -29.25Placebo is the reference
SecondaryPercent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
percent changePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 122.64 ± 1.97-2.00 ± 1.90-28.76 ± 1.97-40.73 ± 1.97-45.09 ± 1.98-29.73 ± 1.91-37.97 ± 1.91-37.66 ± 1.92
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -47.74 · 95% CI -52.18 to -43.29Placebo is the reference
  • Placebo Q2W vs Evolocumab 105 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -43.38 · 95% CI -47.81 to -38.94Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -31.40 · 95% CI -35.83 to -26.97Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -35.65 · 95% CI -39.99 to -31.32Placebo is the reference
  • Placebo Q4W vs Evolocumab 350 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -35.97 · 95% CI -40.29 to -31.65Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -27.73 · 95% CI -32.06 to -23.39Placebo is the reference
SecondaryPercent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12
percent changePlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12-0.30 ± 2.13-0.35 ± 2.38-35.04 ± 2.13-47.60 ± 2.12-53.73 ± 2.14-34.11 ± 2.40-42.74 ± 2.39-43.28 ± 2.40
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -53.44 · 95% CI -58.23 to -48.65Placebo is the reference
  • Placebo Q2W vs Evolocumab 105 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -47.30 · 95% CI -52.08 to -42.52Placebo is the reference
  • Placebo Q2W vs Evolocumab 70 mg Q2W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -34.75 · 95% CI -39.53 to -29.97Placebo is the reference
  • Placebo Q4W vs Evolocumab 420 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -42.93 · 95% CI -48.36 to -37.50Placebo is the reference
  • Placebo Q4W vs Evolocumab 350 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -42.40 · 95% CI -47.81 to -36.98Placebo is the reference
  • Placebo Q4W vs Evolocumab 280 mg Q4W · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -33.77 · 95% CI -39.20 to -28.33Placebo is the reference

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W—4/78 (5.1%)15/78 (19.2%)
Placebo Q4W—0/77 (0%)17/77 (22.1%)
Evolocumab 70 mg Q2W—0/79 (0%)20/79 (25.3%)
Evolocumab 105 mg Q2W—1/79 (1.3%)28/79 (35.4%)
Evolocumab 140 mg Q2W—4/78 (5.1%)27/78 (34.6%)
Evolocumab 280 mg Q4W—2/79 (2.5%)21/79 (26.6%)
Evolocumab 350 mg Q4W—2/79 (2.5%)23/79 (29.1%)
Evolocumab 420 mg Q4W—2/80 (2.5%)30/80 (37.5%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
AnaemiaBlood and lymphatic system disorders0/780/770/790/791/780/790/790/80
Cardiac failure congestiveCardiac disorders0/780/770/790/791/780/790/790/80
Coronary artery diseaseCardiac disorders0/780/770/790/791/780/790/790/80
TachycardiaCardiac disorders0/780/770/790/791/780/790/790/80
PainGeneral disorders0/780/770/790/791/780/790/790/80
Cholecystitis acuteHepatobiliary disorders1/780/770/790/790/780/790/790/80
CellulitisInfections and infestations0/780/770/790/791/780/791/790/80
PneumoniaInfections and infestations0/780/770/790/791/780/791/790/80
Urinary tract infectionInfections and infestations1/780/770/790/790/780/790/790/80
Acetabulum fractureInjury, poisoning and procedural complications0/780/770/790/791/780/790/790/80
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlacebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4W
NasopharyngitisInfections and infestations6/785/779/798/797/788/798/798/80
InfluenzaInfections and infestations2/781/773/793/796/780/791/790/80
CoughRespiratory, thoracic and mediastinal disorders1/782/773/793/790/786/791/793/80
ArthralgiaMusculoskeletal and connective tissue disorders0/783/774/795/792/780/791/791/80
FatigueGeneral disorders1/780/770/791/791/780/792/795/80
Upper respiratory tract infectionInfections and infestations2/782/772/793/794/780/790/794/80
HeadacheNervous system disorders2/780/771/791/794/781/792/792/80
DiarrhoeaGastrointestinal disorders2/782/771/794/792/781/792/793/80
NauseaGastrointestinal disorders1/780/770/791/793/784/793/794/80
Back painMusculoskeletal and connective tissue disorders1/781/770/792/792/784/793/793/80

Baseline characteristics

Full analysis set (all randomized participants who received at least 1 dose of investigational product).

Age, Continuous
Age, Continuous(years)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
Mean60.2 ± 8.860.1 ± 9.659.4 ± 9.958.8 ± 9.762.4 ± 10.260.3 ± 8.461.9 ± 8.860.9 ± 10.360.5 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
Female4241442545403844319
Male3636355433394136310
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
American Indian or Alaska Native010011003
Asian0213122112
Black or African American6068984950
Native Hawaiian or Other Pacific Islander000102003
White7274726767647270558
Other000002103
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
Hispanic or Latino1650610221
Not Hispanic or Latino7771747972787978608
Stratification Factor: LDL-C Level
Stratification Factor: LDL-C Level(participants)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
< 130 mg/dL5151515152515253412
≥ 130 mg/dL2726282826282727217
Stratification Factor: Baseline Ezetimibe Use
Stratification Factor: Baseline Ezetimibe Use(participants)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
No7169727271727273572
Yes7877777757
LDL-C Concentration
LDL-C Concentration(mg/dL)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
Mean122.2 ± 27.1124.9 ± 30.6121.4 ± 24.4127.4 ± 32.1120.9 ± 25.1122.0 ± 28.8123.2 ± 27.1120.8 ± 26.5122.8 ± 27.7
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL)Placebo Q2WPlacebo Q4WEvolocumab 70 mg Q2WEvolocumab 105 mg Q2WEvolocumab 140 mg Q2WEvolocumab 280 mg Q4WEvolocumab 350 mg Q4WEvolocumab 420 mg Q4WTotal
Mean146.9 ± 29.9150.2 ± 36.5145.3 ± 29.9151.2 ± 37.2145.3 ± 26.2146.3 ± 33.3150.0 ± 29.1144.4 ± 31.2147.4 ± 31.8

3 further baseline measures are reported on the registry.

08

Study locations

100 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Tucson, Arizona 85710, United States
  • Research Site
    Malvern, Arkansas 72104, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Carmichael, California 95608, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Roseville, California 95747, United States
  • Research Site
    Westlake Village, California 91361, United States
  • Research Site
    Colorado Springs, Colorado 80909, United States
  • Research Site
    Littleton, Colorado 80120, United States
  • Research Site
    Daytona Beach, Florida 32117, United States
  • Research Site
    Green Cove Springs, Florida 32043, United States
  • Research Site
    Melbourne, Florida 32901, United States
  • Research Site
    Miami, Florida 33143, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Peoria, Illinois 61614, United States
  • Research Site
    Hammond, Indiana 46320, United States
  • Research Site
    Indianapolis, Indiana 46237, United States
  • Research Site
    Valparaiso, Indiana 46383, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Lexington, Kentucky 40536, United States
  • Research Site
    Auburn, Maine 04210, United States
  • Research Site
    Bangor, Maine 04401, United States
  • Research Site
    Portland, Maine 04101, United States
  • Research Site
    Kalamazoo, Michigan 49048, United States
  • Research Site
    Marquette, Michigan 49855, United States
  • Research Site
    Ypsilanti, Michigan 48197, United States
  • Research Site
    Tupelo, Mississippi 38801, United States
  • Research Site
    Great Falls, Montana 59405, United States
  • Research Site
    Voorhees, New Jersey 08043, United States
  • Research Site
    Cortlandt Manor, New York 10567, United States
  • Research Site
    Williamsville, New York 14221, United States
  • Research Site
    Smithfield, North Carolina 27577, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Canton, Ohio 44708, United States
  • Research Site
    Cincinnati, Ohio 45212, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Dayton, Ohio 45414, United States
  • Research Site
    Mansfield, Ohio 44906, United States
  • Research Site
    Marion, Ohio 43302, United States
  • Research Site
    Sandusky, Ohio 44870, United States
  • Research Site
    Camp Hill, Pennsylvania 17011, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15216, United States
  • Research Site
    York, Pennsylvania 17405, United States
  • Research Site
    Florence, South Carolina 29501, United States
  • Research Site
    Spartanburg, South Carolina 29302, United States
  • Research Site
    Rapid City, South Dakota 57701, United States
  • Research Site
    Jackson, Tennessee 38301, United States
  • Research Site
    Jackson, Tennessee 38305, United States
  • Research Site
    Houston, Texas 77002, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Madison, Wisconsin 53713, United States
  • Research Site
    Burnaby, British Columbia V5G 1T4, Canada
  • Research Site
    Kelowna, British Columbia V1Y 1V6, Canada
  • Research Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Research Site
    Victoria, British Columbia V8T 5G1, Canada
  • Research Site
    Cambridge, Ontario N1R 6V6, Canada
  • Research Site
    Hamilton, Ontario L8L 2X2, Canada
  • Research Site
    London, Ontario N5W 6A2, Canada
  • Research Site
    London, Ontario N6A 5K8, Canada
  • Research Site
    Newmarket, Ontario L3Y 5G8, Canada
  • Research Site
    Oshawa, Ontario L1J 2J9, Canada
  • Research Site
    Oshawa, Ontario L1J 2K1, Canada
  • Research Site
    Sarnia, Ontario N7T 4X3, Canada
  • Research Site
    Scarborough, Ontario M1P 2T7, Canada
  • Research Site
    Sudbury, Ontario P3C 5K7, Canada
  • Research Site
    Toronto, Ontario M8V 3X8, Canada
  • Research Site
    Toronto, Ontario M9V 4B4, Canada
  • Research Site
    Woodstock, Ontario N4S 5P5, Canada
  • Research Site
    Gatineau, Quebec J8Y 6S9, Canada
  • Research Site
    Lachine, Quebec H8S 2E4, Canada
  • Research Site
    Longueuil, Quebec J4N 0C9, Canada
  • Research Site
    Pointe-Claire, Quebec H9R 3J1, Canada
  • Research Site
    Quebec, G1V 4M6, Canada
  • Research Site
    Brno, 603 00, Czechia
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Brno, 656 91, Czechia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Praha 2, 120 00, Czechia
  • Research Site
    Praha 4, 140 21, Czechia
  • Research Site
    Slany, 274 01, Czechia
  • Research Site
    Svitavy, 568 25, Czechia
  • Research Site
    Usti nad Orlici, 562 18, Czechia
  • Research Site
    Znojmo, 669 02, Czechia
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Ballerup, 2750, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Budapest, 1096, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Dunaujvaros, 2400, Hungary
  • Research Site
    Eger, 3300, Hungary
  • Research Site
    Gyula, 5700, Hungary
  • Research Site
    Kecskemet, 6000, Hungary
  • Research Site
    Komarom, 2991, Hungary
  • Research Site
    Mosonmagyarovar, 9200, Hungary
  • Research Site
    Szolnok, 5004, Hungary
  • Research Site
    Zalaegerszeg, 8900, Hungary
09

References and documents

Publications

  • Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS; LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012 Dec 8;380(9858):2007-17. doi: 10.1016/S0140-6736(12)61770-X. Epub 2012 Nov 6. PubMed 23141813 ↗
  • Kohli P, Desai NR, Giugliano RP, Kim JB, Somaratne R, Huang F, Knusel B, McDonald S, Abrahamsen T, Wasserman SM, Scott R, Sabatine MS. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2012;35(7):385-91. doi: 10.1002/clc.22014. Epub 2012 Jun 19. PubMed 22714699 ↗
  • Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation. 2013 Aug 27;128(9):962-9. doi: 10.1161/CIRCULATIONAHA.113.001969. Epub 2013 Jul 24. PubMed 23884353 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Apr 2012, 9 months.

Results were first posted in Oct 2015, 3 years 5 months after primary completion. A results delay was requested in Mar 2013.

Of 30 phase 2 interventional studies under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2011
First posted
Jun 27, 2011
StartActual
Jul 1, 2011
Primary completionActual
Apr 5, 2012
CompletionActual
Apr 5, 2012
Results delay requested
Mar 26, 2013
Results first posted
Oct 1, 2015
Last update
Nov 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01380730
Lead sponsor
Amgen
Collaborators
The TIMI Study Group
Responsible party
Sponsor
First posted
Jun 27, 2011
Start date
Jul 1, 2011
Primary completion
Apr 5, 2012
Completion
Apr 5, 2012
Results posted
Oct 1, 2015
Last update
Nov 15, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion